Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia

Bruskewitz, Reginald C.; Girman, Cynthia J.; Fowler, Jackson E.; Rigby, Odell; Sullivan, Michael J.; Bracken, R. Bruce; Fusilier, Harold A.; Kozlowski, Douglas L.; Kantor, S; Johnson, Erika Katherine; Wang, Daniel Z.; Waldstreicher, Joanne

doi:10.1016/s0090-4295(99)00209-5

Cited by 83 publications

(52 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, serum PSA as well as prostate volume were found to be the predictors of symptom progression in the placebo group in the MTOPS study ( Figure 3). 20 Bruskewitz et al 21 reported on the placebo-treated patients in the 4-year PLESS, and their analysis suggests that with increasing PSA tertiles, there is a linear deterioration of frequency of sexual activity, sexual satisfaction and the perception of overall general health (Figure 4). Although this may have been a surprising finding at the time, it is now clear that there is a relationship between LUTS severity and erectile dysfunction and a variety of sexual health measures.…”

mentioning

confidence: 99%

The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia

Roehrborn

2008

Int J Impot Res

View full text Add to dashboard Cite

Several analyses have demonstrated a clinically useful relationship between serum prostate specific antigen (PSA) and prostate volume in men with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Both prostate volume and serum PSA predict certain aspects of the natural history of LUTS and BPH, and men with higher PSA and larger glands in general have a higher rate of progression measured by various parameters. Serum PSA also predicts the response to certain types of medical therapy in men with LUTS and BPH and is thus useful in the evaluation and management of these patients. Lastly, serum PSA does not loose its usefulness as a cancer marker for prostate cancer even if certain medications reduce serum PSA values predictably by 50%.

show abstract

mentioning

confidence: 99%

The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia

Roehrborn

2008

Int J Impot Res

View full text Add to dashboard Cite

show abstract

“…23 The current study was undertaken to evaluate the impact on QOL and sexual function of such a potency-sparing hormone-deprivation approach, used in a neoadjuvant setting and an adjuvant setting in combination with brachytherapy. In addition, because of the known beneficial effects of androgen deprivation on voiding function, 24 we also sought to determine whether this translated to a superior result in terms of voiding function after brachytherapy. 25 ) were treated with palladium 103 (Pd103) brachytherapy (BTM) and adjuvant hormone therapy (BTMϩH).…”

mentioning

confidence: 99%

Impact of a novel neoadjuvant and adjuvant hormone‐deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy

Miller¹,

Bissonette²,

Bahnson³

et al. 2003

Cancer

View full text Add to dashboard Cite

Two fully fluorinated polymers, poly(tetrafluoroethylene) (PTFE) membranes and poly(tetrafluoroethylene‐co‐hexafluoropropylene) (FEP) films, were modified by graft copolymerization with monoacryloxyethyl phosphate (MAEP) in an aqueous solution at ambient temperature using gamma irradiation. The modified membranes were characterized by XPS, FTIR, and phosphate analysis. A correlation between peak heights in the FTIR PAS spectra and the overall grafting yield was found. Neither the surface coverage (as obtained from XPS multiplex scans) nor the overall grafting yield (as obtained from phosphate analysis) showed simple correlations on the monomer concentrations (20–40%) or the irradiation doses (25–150 kGy) within the ranges investigated. Similar surface coverage was achieved on the PTFE membranes and on the FEP films. In contrast, the overall grafting yields were significantly higher for the PTFE membranes than for the FEP films. The high porosity of the PTFE membranes is the most likely explanation for these differences in grafting. © 2002 Wiley Periodicals, Inc. J Appl Polym Sci 86: 2550–2556, 2002

show abstract

“…Bruskewitz et al 38 analizan los 3.040 pacientes incluidos en el estudio PLESS y que recibieron Finasterida o placebo, durante cuatro años. A partir de los cuatro meses de inicio del estudio, aquellos tratados con Finasterida mejoran sus síntomas lo que implica una reducción significativa de la interferencia de los mismos con la actividad diaria y de la preocupación por dicha sintomatología.…”

Section: Sumar Un Punto a Las Dos Primerasunclassified

Finasterida: diez años de uso clínico. Revisión sistemática de la literatura

Cruz

Gutiérrez²,

Señarís³

2003

Actas Urol Esp

View full text Add to dashboard Cite

RESUMEN"FINASTERIDA: DIEZ AÑOS DE USO CLÍNICO. REVISIÓN SISTEMÁTICA DE LA LITERATURA" INTRODUCCIÓN: Después de diez años de uso clínico de Finasterida en el tratamiento farmacológico de la Hiperplasia Benigna de Próstata (HBP), nos planteamos revisar la literatura, para analizar aquellos trabajos que por diseño y calidad metodológica, nos permita aplicar recomendaciones basadas en evidencias clínicas.MATERIAL Y MÉTODOS: Utilizando las bases de datos informáticas disponibles en Medline, Embase, Healthstar, y la Cochrane Library (1990Library ( -2002, se recogieron todos los trabajos referentes a pacientes entre 50 y 85 años, con síntomas del tramo urinario inferior sugerentes de HBP y con parámetros objetivos, como flujometría, medición del volumen prostático y del residuo post-miccional, presión del detrusor, efectos adversos, costeefectividad, calidad de vida.RESULTADOS: Se encontraron un total de 137 referencias, de las cuales 36 cumplen los criterios de inclusión, que permiten su clasificación por niveles de evidencia. Tres tienen nivel I, 12 nivel II, 6 nivel III y 10 nivel IV. Tres son estudios económicos y dos evalúan calidad de vida.COMENTARIOS: Con alto nivel de evidencia y después de diez años de uso, se demuestra que Finasterida es efectivo en reducir la sintomatología en los pacientes con próstatas mayores de 40 ml y/o PSA >1,4 ngr/ml, con escasos efectos adversos y una clara mejoría en la calidad de vida, por lo que es recomendable con grado A, su uso clínico.CONCLUSIONES: Finasterida, al reducir el volumen prostático (nivel de evidencia I), modifica la evolución natural de la HBP, disminuyendo el riesgo de retención aguda de orina y de cirugía.PALABRAS CLAVE: Hiperplasia Benigna de Próstata. Finasterida. Medicina basada en la Evidencia. Calidad de Vida. ABSTRACT "FINASTERIDE: TEN YEARS OF CLINICAL USE. SISTEMATIC REVISION OF BIBLIOGHRAPHY" INTRODUCTION:After ten years of clinical use of Finasteride in patientes with BPH, we carried out a systematic review of the literature including the assessment of their quality and grading the level of evidence for clinical recommendations.METHODS: Using Medline, Embase, Healthstar and Cochrane Library from 1990 until 2002, we select all the studies refering patients between 50 to 85 with symptoms of BPH, metrics of flow, prostatic volume, postmictional residue, detrusor pressure, adverse effects, cost-efecctiveness and quality of life.RESULTS: We found out 135 references, of which 36 accomplish the inclusion criteria. Of those, 3 have got level I of evidence, 12 level II, 6 level III and 10 level IV. Three are economic studies and two evaluate the quality of life. DISCUSSION: With a high level of evidence and after ten years of clinical use, Finasteride shows its effectiveness in reducing the symptoms of patients with prostate bigger than 40 ml and/or PSA of more than 1.4 ngr/ml, with scarce adverse effects with a clear improvement of quality of life. Therefore, it is recommended (grade A) for clinical use.CONCLUSIONS: Finasteride, through prostate volume reducti...

show abstract

Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia

Cited by 83 publications

References 34 publications

The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia

The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia

Impact of a novel neoadjuvant and adjuvant hormone‐deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy

Finasterida: diez años de uso clínico. Revisión sistemática de la literatura

Contact Info

Product

Resources

About